Core Viewpoint - Baoyi Pharmaceutical-B (02659) has shown strong performance in the dark market, with a trading price of HKD 54, representing a 104.7% increase from the IPO price of HKD 26.38, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Company Overview - Baoyi Pharmaceutical was established in 2019 and is headquartered in Shanghai, China, focusing on developing and providing recombinant biopharmaceuticals using advanced synthetic biotechnology [2] - The company has a pipeline of 12 self-developed products, including three core products (KJ017, KJ103, and SJ02), four other clinical candidates, and five preclinical assets [2] Group 2: Product and Market Potential - The core products and major assets of Baoyi Pharmaceutical are focused on four key therapeutic areas, including high-volume subcutaneous administration, antibody-mediated autoimmune diseases, assisted reproductive drugs, and innovative recombinant biopharmaceuticals [3] - The total clinical addressable market size for Baoyi Pharmaceutical's four strategic therapeutic areas in China is projected to reach approximately RMB 50 billion by 2033, with significant contributions from various segments [4] - The company has established a GMP-compliant production facility in Shanghai, covering approximately 63,000 square meters, equipped with specialized production lines for complex biopharmaceuticals [4] Group 3: Investment and Future Outlook - The IPO has attracted a strong lineup of cornerstone investors, with three well-known investment institutions participating, collectively subscribing to HKD 200.6 million, accounting for 20.06% of the total fundraising [1] - With sufficient funding and a clear strategy, Baoyi Pharmaceutical is expected to accelerate the commercialization of its core products and translate its technological advantages into tangible performance growth [4]
暗盘表现强劲！宝济药业-B即将登陆港交所 聚焦大容量皮下给药、自身免疫等领域